Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business

Servier agreed to acquire Edgewise Therapeutics' (Nasdaq:EWTX) muscular dystrophy business for up to $2.65 billion.

Rhea-AI Summary

Servier agreed to acquire Edgewise Therapeutics' (Nasdaq:EWTX) muscular dystrophy business for up to $2.65 billion. The deal includes an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestones, and is expected to close in Q3 2026, subject to regulatory clearance.

The transaction adds sevasemten, an orally administered fast skeletal myosin inhibitor in a pivotal Becker muscular dystrophy cohort and phase 2 Duchenne study, along with associated neuromuscular capabilities.

Positive

• Total transaction value up to $2.65 billion
• Upfront cash payment of $1.55 billion
• Additional up to $1.1 billion in milestone payments
• Servier gains late-stage sevasemten for BMD and phase 2 DMD
• Acquisition expected to close in Q3 2026, pending approvals

Negative

• Closing is subject to regulatory clearance and customary conditions
• Up to $1.1 billion is contingent on future milestones

Argus Jun 1 session

+17.86% close to close Open Argus

Details

News Market Reaction – EWTX

In the Jun 1 session, EWTX gained 17.86%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +17.9% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +17.9% in the session following this news. A strong positive reaction aligns with the substantial upfront value of the Servier transaction, which assigns up to $2.65B to Edgewise’s muscular dystrophy business. Past clinical updates, such as the long‑term sevasemten data, also drew positive responses. Investors would still need to weigh execution risks through the expected 3Q 2026 closing and the company’s remaining pipeline beyond the divested assets when assessing how durable such a move might be.

Key Figures

Deal value: $2.65 billion Upfront payment: $1.55 billion Milestone payments: $1.1 billion +4 more

Deal value

$2.65 billion

Total transaction value for muscular dystrophy business

Upfront payment

$1.55 billion

Cash consideration at closing from Servier

Milestone payments

$1.1 billion

Regulatory and commercial milestones contingent on progress

Sevasemten stage BMD

Pivotal cohort

Sevasemten in pivotal cohort for Becker muscular dystrophy

Sevasemten stage DMD

Phase 2

Sevasemten in Phase 2 for Duchenne muscular dystrophy

Median life expectancy

30 years

Median life expectancy for Duchenne muscular dystrophy

Expected closing

Q3 2026

Target close for Servier acquisition, subject to clearances

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Conference appearance

   24h Move

   -1.6%

   Announcement of presentation at RBC healthcare conference with webcast access.

2. May 07

   Earnings and pipeline

   24h Move

   -3.8%

   Q1 2026 results showing higher R&D spend and larger net loss.

3. May 04

   Inducement grants

   24h Move

   +2.7%

   Stock option inducement grants to new employees under equity plan.

4. Apr 01

   Inducement grants

   24h Move

   +5.2%

   Additional inducement option grants with multi-year vesting schedule.

5. Mar 10

   Clinical data update

   24h Move

   +2.2%

   Positive long‑term sevasemten data in Becker muscular dystrophy and pivotal plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

becker muscular dystrophy, duchenne muscular dystrophy, fast skeletal myosin inhibitor, pivotal cohort, +2 more

6 terms

becker muscular dystrophy medical

"Sevasemten is currently investigated in a pivotal cohort in Becker muscular dystrophy (BMD)"

A genetic muscle disorder that causes progressive weakness and tissue loss because the dystrophin protein is reduced or abnormal, typically affecting males with a wide range of severity. For investors, it matters because the condition defines a small, well-characterized patient group and a clear biological target, which shapes clinical trial design, regulatory incentives and the potential market for specialized therapies or diagnostics—think of it as a known structural defect companies can aim to fix.

duchenne muscular dystrophy medical

"and in phase 2 in Duchenne muscular dystrophy (DMD)."

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

fast skeletal myosin inhibitor medical

"first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle"

A fast skeletal myosin inhibitor is a drug that targets the specific protein (myosin) responsible for contractions in fast-twitch skeletal muscle fibers, effectively turning down those muscles’ force like a dimmer switch on a light. Investors care because this selective mechanism can treat conditions caused by excessive or uncontrolled muscle contractions without broadly weakening all muscles, which affects clinical trial outcomes, regulatory approval prospects, market size, and commercial risk.

pivotal cohort medical

"Sevasemten is currently investigated in a pivotal cohort in Becker muscular dystrophy"

A pivotal cohort is the main group of patients in a clinical trial whose results regulators and companies treat as the decisive test of a treatment’s safety and effectiveness. Investors pay attention because outcomes from this group often determine whether a product can win approval or reach the market, similar to a final exam or spotlight performance that can make or break a company’s prospects.

phase 2 medical

"and in phase 2 in Duchenne muscular dystrophy (DMD)."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

regulatory clearance regulatory

"The transaction is subject to regulatory clearance and customary closing conditions"

Regulatory clearance is official permission from a government agency to market, sell, or use a product or service after it meets required safety, quality, or performance standards. For investors it matters because receiving clearance often unlocks revenue, lowers legal and commercial risk, and can materially change a company’s growth outlook—think of it like a driver’s license that legally allows a product to be driven onto the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.
• Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies.
• Transaction represents total value of up to $2.65 billion.

SURESNES, France, June 1, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), a biopharmaceutical company focused on developing innovative therapies for serious muscle disorders, for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments. The transaction has been approved by both companies' respective governance bodies. The transaction is subject to regulatory clearance and customary closing conditions and is expected to close in the third quarter of 2026.

This acquisition of Edgewise Therapeutics' muscular dystrophy business includes its associated capabilities as well as sevasemten, an investigational orally administered first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with rare muscular dystrophy. Sevasemten is currently investigated in a pivotal cohort in Becker muscular dystrophy (BMD), and in phase 2 in Duchenne muscular dystrophy (DMD). This drug candidate has the potential to position Servier as a global player with strong capabilities and a pipeline in neuromuscular disorders.  

Becker muscular dystrophy is a rare, X-linked genetic disorder that causes progressive muscle loss, with currently no approved treatment for patients. The loss of muscle function is irreversible and impacts patients' abilities to perform everyday activities like walking. Duchenne muscular dystrophy is a more severe, recessive X-linked genetic, degenerative muscle disorder beginning at birth that causes patients to lose their walking ability by their early teens. It is the most common type of muscular dystrophy with a median life expectancy of around 30 years.

"The acquisition of Edgewise Therapeutics' muscular dystrophy business is a key step forward to achieve our Servier 2030 ambition in neurology with a team of talented experts and a promising asset in muscular dystrophies", said Olivier Laureau, President of Servier. "This acquisition aims to provide targeted therapies to patients with rare neuromuscular disorders. Developing treatments for young and adult patients, with highly debilitating rare conditions and limited to no options today, is at the heart of our mission."

"We believe Servier is well positioned to advance sevasemten and the muscular dystrophy program given its commitment to patients, growing focus in neurology, and global development capabilities," said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics. "This transaction is designed to place the program in the hands of an organization with the experience and infrastructure to support its continued development for people living with Becker and Duchenne muscular dystrophies." 

PDF - https://mma.prnewswire.com/media/2991923/Servier_English.pdf
Logo - https://mma.prnewswire.com/media/2766991/Servier_Logo.jpg

Contacts

Servier Group
Laura Visserias
laura.visserias.part@servier.com  

Servier Pharmaceuticals (U.S.)
Kenneth Dicienzo
Kenneth.dicienzo@servier.com

 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/servier-to-acquire-edgewise-therapeutics-muscular-dystrophy-business-302787017.html

SOURCE Servier

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Servier announce about acquiring Edgewise Therapeutics' (EWTX) muscular dystrophy business?

Servier announced an agreement to acquire Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion. According to Servier, the deal includes sevasemten and related neuromuscular capabilities, strengthening its rare neurology pipeline and presence in muscular dystrophies.

What is the total deal value and payment structure in the Servier and Edgewise (EWTX) transaction?

The transaction is valued at up to $2.65 billion, combining upfront and milestone payments. According to Servier, Edgewise will receive $1.55 billion upfront and up to $1.1 billion in additional regulatory and commercial milestone payments linked to the muscular dystrophy programs.

When is the Servier acquisition of Edgewise Therapeutics' (EWTX) muscular dystrophy business expected to close?

The acquisition is expected to close in the third quarter of 2026. According to Servier, completion depends on regulatory clearance and customary closing conditions, which must be satisfied before transferring the muscular dystrophy business and associated assets.

What is sevasemten in the Servier and Edgewise (EWTX) muscular dystrophy deal?

Sevasemten is an orally administered investigational fast skeletal myosin inhibitor targeting muscular dystrophies. According to Servier, it is in a pivotal Becker muscular dystrophy cohort and phase 2 Duchenne muscular dystrophy trial, aiming to protect unstable muscle from contraction-induced damage.

How does the Servier and Edgewise (EWTX) deal affect Becker muscular dystrophy treatment development?

The deal moves Edgewise’s Becker muscular dystrophy program, including sevasemten, under Servier’s neurology strategy. According to Servier, sevasemten is being studied in a pivotal Becker cohort and could help address an area with no currently approved treatments.

What are the clinical stages of sevasemten for Duchenne and Becker muscular dystrophy in the Servier–Edgewise (EWTX) agreement?

Sevasemten is in a pivotal cohort for Becker muscular dystrophy and phase 2 for Duchenne. According to Servier, these studies evaluate its potential to preserve muscle and support development in rare neuromuscular disorders with high unmet needs.